The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 34 | — | 20.1x | Near average | |
Growth | 4 | — | 5.6% | Below average | |
Quality | 7 | -240.2% | 7.6% | Below average | |
Safety | 30 | 0.5x | 0.4x | Below average | |
Capital Return | 20 | 0.00% | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
NextCure, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy NextCure, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
NextCure stock shows a state of complete stability in analyst estimates across timeframes (1, 7, 30 days), with the target price stabilizing at 15 dollars. This consistency reflects the absence of any recent revisions or near-term catalysts that led to a change in investment convictions, noting that the estimate currently depends on only one analyst, which raises the risk level associated with forecast concentration and the lack of diversity in analytical opinions.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.